Longevity & AgingFDA adds NAION eye warning to GLP-1 drugs, leaving patients and doctors in a bind
The FDA announced on November 9 that all GLP-1 drugs, including semaglutide and tirzepatide, must carry new warnings about a possible increased risk of NAION, a rare form of sudden, painless vision loss caused by reduced blood flow to the optic nerve. This opinion piece, by ophthalmologist Henry Bair, argues the warning is welcome but incomplete. Across 126 clinical trials, the FDA found 15 probable cases: about six per 100,000 patient-years on GLP-1 drugs versus four on placebo or other diabetes drugs. Observational studies also raise concern, but they cannot fully separate drug effects from the underlying conditions. No one knows whether continuing a GLP-1 after NAION raises risk in the other eye, or whether stopping lowers it. Bair urges the FDA to study outcomes after stopping, continuing or switching. Until then, he recommends that patient, eye doctor and prescriber weigh the decision together.